Chiao-Ling Tsai1, Feng-Ming Hsu2, Jason Chia-Hsien Cheng3. 1. Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (ROC); Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan (ROC). 2. Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (ROC). 3. Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (ROC); Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan (ROC).
Abstract
BACKGROUND: During the past two decades, external-beam radiation technology has substantially changed from traditional two-dimensional to conformal three-dimensional to intensity-modulated planning and stereotactic body radiotherapy (SBRT). SUMMARY: Modern techniques of radiotherapy (RT) are highly focused and capable of delivering an ablative dose to targeted hepatocellular carcinoma (HCC) tumors. SBRT is an option for selected patients with limited tumor volume and non-eligibility for other invasive treatments. Moreover, RT combined with a radiation sensitizer (RS) to increase the therapeutic ratio has shown promising results in select studies, prompting further investigation of this combination. With the undetermined role of RT in treatment guidelines and variation in patterns of treatment failure after RT in patient with HCC, useful biomarkers to guide RT decision-making and selection of patients are needed and emerging. KEY MESSAGE: The objective of this review is to summarize the current RS with SBRT schemes and biomarkers for patient selection used to maximize the effect of RT on HCC.
BACKGROUND: During the past two decades, external-beam radiation technology has substantially changed from traditional two-dimensional to conformal three-dimensional to intensity-modulated planning and stereotactic body radiotherapy (SBRT). SUMMARY: Modern techniques of radiotherapy (RT) are highly focused and capable of delivering an ablative dose to targeted hepatocellular carcinoma (HCC) tumors. SBRT is an option for selected patients with limited tumor volume and non-eligibility for other invasive treatments. Moreover, RT combined with a radiation sensitizer (RS) to increase the therapeutic ratio has shown promising results in select studies, prompting further investigation of this combination. With the undetermined role of RT in treatment guidelines and variation in patterns of treatment failure after RT in patient with HCC, useful biomarkers to guide RT decision-making and selection of patients are needed and emerging. KEY MESSAGE: The objective of this review is to summarize the current RS with SBRT schemes and biomarkers for patient selection used to maximize the effect of RT on HCC.
Authors: L A Dawson; C J McGinn; D Normolle; R K Ten Haken; S Walker; W Ensminger; T S Lawrence Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: Riccardo Lencioni; Thierry de Baere; Robert C Martin; Charles W Nutting; Govindarajan Narayanan Journal: Liver Cancer Date: 2015-10-21 Impact factor: 11.740
Authors: Tatjana Paunesku; Andrew C Gordon; Sarah White; Kathleen Harris; Olga Antipova; Evan Maxey; Stefan Vogt; Anthony Smith; Luiza Daddario; Daniele Procissi; Andrew Larson; Gayle E Woloschak Journal: Front Public Health Date: 2021-08-20